Matteo G. Carrabba

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

The conditional benefit of being alive and disease free at 2 years after transplant: a long term survival evaluation among 456 patients affected by acute myeloid leukemia.

The conditional benefit of being alive and disease free at 2 years after transplant: a long term survival evaluation among 456 patients affected by acute myeloid leukemia.

Journal: Frontiers in immunology

Published: February 26, 2026

Therapy induced senescence promotes immunogenicity in acute myeloid Leukemia through reduced EZH2 activity.

Therapy induced senescence promotes immunogenicity in acute myeloid Leukemia through reduced EZH2 activity.

Journal: Nature communications

Published: August 27, 2025

Tumor-targeted interferon-α gene therapy for glioblastoma: a phase 1 trial.

Tumor-targeted interferon-α gene therapy for glioblastoma: a phase 1 trial.

Journal: Nature medicine

Published: June 18, 2025

Biomarkers for an early diagnosis of immune effector cell associated-hemophagocytic syndrome.

Biomarkers for an early diagnosis of immune effector cell associated-hemophagocytic syndrome.

Journal: Frontiers in immunology

Published: May 25, 2025

Impact of Respiratory Syncytial Virus (RSV) on adult haematology oncology patients.

Impact of Respiratory Syncytial Virus (RSV) on adult haematology oncology patients.

Journal: The Journal of infection

Published: October 17, 2024

Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non-low-risk AML.

Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non-low-risk AML.

Journal: Blood advances

Published: September 23, 2024

Spontaneous remission of choroidal involvement by chronic myelomonocytic leukemia: a case report.

Spontaneous remission of choroidal involvement by chronic myelomonocytic leukemia: a case report.

Journal: Frontiers in oncology

Published: March 12, 2024

A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas.

A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas.

Journal: Blood cancer discovery

Published: February 24, 2024

Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations.

Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations.

Journal: Blood

Published: March 27, 2023

Impact of tixagevimab/cilgavimab prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplants and CAR T-cell therapy: A single center experience.

Impact of tixagevimab/cilgavimab prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplants and CAR T-cell therapy: A single center experience.

Journal: Current research in translational medicine

Published: March 17, 2023

Case report: Ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed/refractory Philadelphia-like acute lymphoblastic leukemia.

Case report: Ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed/refractory Philadelphia-like acute lymphoblastic leukemia.

Journal: Frontiers in oncology

Published: November 16, 2022

Levofloxacin prophylaxis vs no prophylaxis in patients with neutropenia within an endemic country for carbapenem-resistant GNB.

Levofloxacin prophylaxis vs no prophylaxis in patients with neutropenia within an endemic country for carbapenem-resistant GNB.

Journal: Blood advances

Published: May 31, 2022

Showing 1-12 of 50

Last Updated: 09/26/2026